Kidswell Bio Corporation (4584)

Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
Period EndReturn on equity (%) (Million JPY)YoY (%)
Mar 31, 2025-1.9-98.63%
Mar 31, 2024-137.7+209.23%
Mar 31, 2023-44.5+38.50%
Mar 31, 2022-32.2-50.26%
Mar 31, 2021-64.7-81.36%
Mar 31, 2020-346.9+980.56%
Mar 31, 2019-32.1+8.30%
Mar 31, 2018-29.6-52.76%
Mar 31, 2017-62.7-73.16%
Mar 31, 2016-233.7+95.26%
Mar 31, 2015-119.7
AI Chat